Cullen/Frost Bankers, Inc. Janux Therapeutics, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $6.83 Billion
- Q2 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 169 shares of JANX stock, worth $9,191. This represents 0.0% of its overall portfolio holdings.
Number of Shares
169Holding current value
$9,191% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
160Shares Held
37.2MCall Options Held
70.4KPut Options Held
101K-
Ra Capital Management, L.P. Boston, MA9.17MShares$499 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$162 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$127 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$127 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$98 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.27B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...